Sheets Smith Wealth Management Has $1.62 Million Stock Position in ImmunityBio, Inc. (NASDAQ:IBRX)

Sheets Smith Wealth Management lessened its stake in ImmunityBio, Inc. (NASDAQ:IBRX) by 4.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 633,975 shares of the company’s stock after selling 32,020 shares during the quarter. Sheets Smith Wealth Management owned about 0.09% of ImmunityBio worth $1,623,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in IBRX. State Street Corp increased its holdings in ImmunityBio by 10.1% during the 3rd quarter. State Street Corp now owns 8,654,460 shares of the company’s stock worth $32,195,000 after purchasing an additional 790,408 shares in the last quarter. Barclays PLC grew its holdings in shares of ImmunityBio by 127.4% during the third quarter. Barclays PLC now owns 361,036 shares of the company’s stock worth $1,344,000 after buying an additional 202,248 shares in the last quarter. B. Riley Wealth Advisors Inc. acquired a new stake in ImmunityBio in the 2nd quarter valued at approximately $515,000. GSA Capital Partners LLP lifted its stake in ImmunityBio by 290.3% in the 3rd quarter. GSA Capital Partners LLP now owns 107,985 shares of the company’s stock valued at $402,000 after acquiring an additional 80,318 shares in the last quarter. Finally, XTX Topco Ltd boosted its position in ImmunityBio by 309.4% during the 3rd quarter. XTX Topco Ltd now owns 92,910 shares of the company’s stock worth $346,000 after acquiring an additional 70,215 shares during the last quarter. Institutional investors and hedge funds own 8.58% of the company’s stock.

ImmunityBio Trading Up 9.5 %

Shares of IBRX stock opened at $3.22 on Wednesday. ImmunityBio, Inc. has a 1 year low of $2.28 and a 1 year high of $10.53. The stock has a 50 day simple moving average of $3.60 and a 200 day simple moving average of $4.15.

Analyst Upgrades and Downgrades

IBRX has been the topic of a number of recent analyst reports. D. Boral Capital reissued a “buy” rating and set a $30.00 price target on shares of ImmunityBio in a research report on Thursday, January 16th. EF Hutton Acquisition Co. I raised ImmunityBio to a “strong-buy” rating in a report on Wednesday, October 23rd. Finally, BTIG Research assumed coverage on ImmunityBio in a research report on Friday, January 10th. They set a “buy” rating and a $6.00 price objective on the stock.

ImmunityBio Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.